Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam blood-brain barrier penetration and PK/PD study in carbapenem-resistant gram-negative CNS infection
ChiCTR2100048778Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Mar 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ceftazidime + avibactam in Central nervous system infection, bacterial meningitis, ventriculitis and 1 more, sponsored by Huashan Hospital. Primary endpoints: Drug concentration in plasma, Drug concentration in cerebrospinal fluid and 6 more. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
ceftazidime + avibactam
03
Conditions
Central nervous system infectionbacterial meningitisventriculitisGram-negative bacterial infection
Beyond the preview
Go deeper on ChiCTR2100048778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048778.